Pemphigus Vulgaris

What Is Pemphigus Vulgaris?

Pemphigus vulgaris is a rare but serious autoimmune blistering disease in which the immune system mistakenly produces antibodies against proteins that normally hold skin cells firmly together. This misdirected immune attack causes the cells within the outer layer of skin to separate from one another, resulting in painful blisters and erosions.¹

Unlike some other blistering skin conditions, pemphigus vulgaris frequently begins in the mouth, often affecting the mucous membranes before skin lesions ever appear, and it can also involve other mucosal surfaces throughout the body, including the throat, nose, eyes, and genitals.¹

Before the development of modern immunosuppressive treatment, pemphigus vulgaris carried an extremely high mortality rate. While treatment has dramatically improved outcomes over recent decades, the condition remains a serious diagnosis requiring careful, ongoing medical management to control disease activity and prevent complications.²

Pemphigus vulgaris is an immunobullous condition caused by autoantibodies targeting the adhesion proteins of desmosomes, leading to blistering in the skin and mucosal membranes.
National Center for Biotechnology Information

Symptoms

Painful sores in the mouth are often the first symptom of pemphigus vulgaris, frequently preceding skin involvement by weeks or even months, and these oral erosions can make eating, drinking, and even speaking uncomfortable for affected patients.¹

Skin involvement typically follows, producing flaccid, easily ruptured blisters on skin that otherwise appears normal, distinguishing pemphigus vulgaris from some other blistering conditions in which blisters tend to be firmer and more resistant to rupture.¹

Because the blisters associated with pemphigus vulgaris break so easily, patients often present not with intact blisters but with painful, raw erosions where blisters have already ruptured, and these areas can be extensive and slow to heal without appropriate treatment.¹

Causes

Pemphigus vulgaris results from autoantibodies that specifically target desmoglein proteins, structural components essential for maintaining the connections between adjacent skin cells within a structure called the desmosome.¹

Desmoglein three, targeted in the majority of pemphigus vulgaris cases, plays a central structural role in mucosal tissue, which helps explain why oral involvement is so often the earliest and most prominent feature of the disease. Many patients also develop antibodies against a second protein, desmoglein one, and the specific combination of antibodies present influences whether a patient experiences primarily mucosal or combined mucosal and skin involvement.³

When these antibodies bind to their target proteins, they disrupt the normal function of desmosomes, causing the connections between skin cells to fail in a process called acantholysis, ultimately allowing fluid to accumulate and blisters to form within the affected tissue.¹

Risk Factors

Pemphigus vulgaris can affect people of any age but is diagnosed most frequently in middle aged and older adults, typically between the ages of forty and sixty, though it can occasionally occur in younger individuals as well.¹

Certain populations, including people of Ashkenazi Jewish and Mediterranean descent, appear to experience higher rates of pemphigus vulgaris, suggesting a meaningful genetic component to individual disease susceptibility.¹

A rare but important related condition, paraneoplastic pemphigus, can develop in association with certain underlying cancers, particularly blood cancers such as chronic lymphocytic leukemia, representing a distinct disease process that requires its own specific diagnostic and treatment considerations.⁴

Complications

Because pemphigus vulgaris causes widespread breakdown of the skin’s protective barrier, affected patients face significantly elevated risk of secondary bacterial infection, fluid loss, and, in severe or extensive cases, complications similar to those seen with major burns.¹

Historically, mortality associated with pemphigus vulgaris was extremely high before effective treatment became available. Even with modern therapy, reported mortality rates remain meaningfully elevated, ranging from roughly five to fifteen percent, reflecting both the severity of the disease itself and complications related to long term immunosuppressive treatment.⁵

Persistent oral involvement can significantly affect nutrition and quality of life, since painful mouth erosions often make eating difficult, and extensive skin involvement can be similarly disabling, underscoring why prompt, effective treatment matters so much for this condition.¹

Treatment

Systemic corticosteroids have traditionally served as the initial treatment for pemphigus vulgaris, working to broadly suppress the underlying immune response responsible for antibody production and ongoing blister formation.²

For patients who do not respond adequately to corticosteroids alone, or who require unacceptably high steroid doses for adequate control, rituximab, a monoclonal antibody that depletes specific immune cells responsible for antibody production, has become an increasingly important treatment option, with strong evidence supporting both its effectiveness and relatively favorable safety profile.⁶

Early use of rituximab, rather than reserving it only for patients who fail other treatments, has been associated with improved outcomes and reduced corticosteroid requirements in several studies, contributing to a meaningful shift in how pemphigus vulgaris is managed in current clinical practice.⁷

Prevention

Because the precise trigger for pemphigus vulgaris in any given individual generally cannot be identified, there is no established or proven way to prevent the condition from developing.¹

Early recognition of persistent, unexplained mouth sores or unusual skin blistering allows treatment to begin as promptly as possible, which offers the best opportunity to control disease activity before extensive skin or mucosal involvement develops.¹

For patients already diagnosed and receiving treatment, consistent monitoring for infection, careful attention to nutrition during periods of active oral disease, and close follow up with a dermatologist experienced in managing this condition all help reduce the risk of the serious complications historically associated with pemphigus vulgaris.⁵

Why Visual Communication Matters for Pemphigus Vulgaris

Explaining how antibodies can specifically target the microscopic structures holding skin cells together, or why treatment now focuses on depleting the specific immune cells responsible for producing those antibodies, requires visuals that make an intricate autoimmune process genuinely understandable to patients facing a serious and often frightening diagnosis.¹

Pharmaceutical companies, dermatology practices, and patient advocacy organizations rely on precise illustration and animation to explain the biology behind pemphigus vulgaris and the treatments now available to manage it.

• Illustrating desmosome structure and how autoantibody binding disrupts cell adhesion
• Animating the acantholysis process underlying blister formation in pemphigus vulgaris
• Explaining the mechanism of action for corticosteroid and rituximab therapy
• Visualizing the difference between mucosal and skin involvement based on antibody targets
• Supporting patient education on early recognition and treatment urgency
• Creating training materials for clinicians on diagnosis and treatment sequencing

How Biotic Artlab Supports Pemphigus Vulgaris Communication

We work with pharmaceutical companies, dermatology practices, and patient advocacy organizations to create accurate, engaging visuals that make the biology of pemphigus vulgaris and its treatment easier to understand for patients and clinicians alike.

• Custom 3D animations of desmosome disruption and blister formation
• Detailed illustrations of oral and skin involvement in pemphigus vulgaris
• Mechanism of action animations for corticosteroid and B cell depleting therapies
• Patient facing educational materials on symptom recognition and care
• Clinical training content for dermatology teams on treatment sequencing
• Conference presentations and marketing visuals for dermatology audiences

Frequently Asked Questions

Is pemphigus vulgaris contagious?

No. Pemphigus vulgaris is an autoimmune condition, not an infection, and cannot be spread from person to person through contact of any kind.¹

Why does pemphigus vulgaris often start in the mouth?

The protein most commonly targeted by pemphigus vulgaris antibodies, desmoglein three, plays a particularly important structural role in mucosal tissue, which helps explain why oral symptoms frequently appear before skin involvement.³

Is pemphigus vulgaris life threatening?

It can be, particularly if untreated or poorly controlled. Reported mortality rates remain meaningfully elevated even with modern treatment, ranging from roughly five to fifteen percent, reflecting the seriousness of this condition.⁵

What is rituximab and how does it help pemphigus vulgaris?

Rituximab is a monoclonal antibody that depletes specific immune cells responsible for producing the harmful antibodies driving pemphigus vulgaris, offering an effective treatment option, particularly for patients who do not respond adequately to corticosteroids alone.⁶

How is pemphigus vulgaris different from bullous pemphigoid?

Although both are autoimmune blistering diseases, pemphigus vulgaris typically produces more fragile blisters, frequently begins in the mouth, and results from a different set of target proteins compared with bullous pemphigoid, which more commonly affects older adults and produces firmer, more resilient blisters.¹

Can pemphigus vulgaris be cured?

There is currently no permanent cure, but modern treatment, particularly with rituximab, can achieve durable remission for many patients, meaningfully improving outcomes compared with treatment approaches available in past decades.⁷

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to pemphigus vulgaris or autoimmune skin disease, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information, StatPearls. Pemphigus Vulgaris.
2. National Center for Biotechnology Information. Diagnosis and Treatment Challenges of an Atypical Case of Pemphigus Vulgaris During the COVID 19 Pandemic.
3. National Center for Biotechnology Information. Evaluation of Desmoglein 1 and 3 Autoantibodies in Pemphigus Vulgaris, Correlation With Disease Severity.
4. National Center for Biotechnology Information. Paraneoplastic Pemphigus Associated With B Cell Chronic Lymphocytic Leukemia Treated With Ibrutinib and Rituximab.
5. National Center for Biotechnology Information. Mortality Rates Among Individuals Diagnosed With Pemphigus, 12 Year Experience in Tehran, Iran.
6. National Center for Biotechnology Information. Rituximab Therapy Improves Recalcitrant Pemphigus Vulgaris.
7. National Center for Biotechnology Information. Clinical Impact and a Prognostic Marker of Early Rituximab Treatment After Rituximab Reimbursement in Korean Pemphigus Patients.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.